GLP-1 Medications 2026: A Las Vegas & Henderson Physician's Guide
LiveNow Longevity
Semaglutide and tirzepatide have FDA-approved products for specific indications; retatrutide remains investigational. It is not a third routine prescribing option. FDA states that retatrutide cannot be compounded under federal law. The mechanisms are GLP-1 for semaglutide, GIP/GLP-1 for tirzepatide and GLP-1/GIP/glucagon for investigational retatrutide. Discuss approved treatment decisions with a clinician.
What GLP-1 medications are available in 2026?
Semaglutide and tirzepatide have FDA-approved products for specific indications; retatrutide remains investigational. It is not a third routine prescribing option. FDA states that retatrutide cannot be compounded under federal law. The mechanisms are GLP-1 for semaglutide, GIP/GLP-1 for tirzepatide and GLP-1/GIP/glucagon for investigational retatrutide. Discuss approved treatment decisions with a clinician.
- Semaglutide - a single GLP-1 receptor agonist, FDA-approved for chronic weight management.[2]
- Tirzepatide - a dual GLP-1/GIP agonist, FDA-approved for chronic weight management.[1]
- Retatrutide - an investigational triple-receptor agonist, not FDA-approved. It cannot be compounded under federal law.
The 2026 Options at a Glance
The practical differences between these three come down to how many receptors each engages, whether it is approved, and what evidence exists behind it. That last column is where the gap between them is widest.
| Medication | Receptors | Status for weight management | Evidence stage |
|---|---|---|---|
| Semaglutide | GLP-1 | FDA-approved | Phase 3 completed - STEP 1 reported −14.9% mean weight change at 68 weeks[2] |
| Tirzepatide | GLP-1 + GIP | FDA-approved | Phase 3 completed - SURMOUNT-1 reported −15.0% to −20.9% across doses at 72 weeks[1] |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational; not FDA-approved and cannot be legally compounded. | Phase 2 only at the time of the trial published in 2023[3] |
How do GLP-1, GIP, and glucagon work for weight loss?
Each added receptor gives the medication another lever on appetite and metabolism. GLP-1 slows gastric emptying and signals fullness through appetite centers in the brain. GIP, a second incretin hormone, sharpens the insulin response and influences how fat tissue handles nutrients. Glucagon, retatrutide's third target, raises energy expenditure and helps mobilize stored fat.
Appetite is regulated in the brain, not the stomach - GLP-1 receptors sit in the hypothalamic and brainstem circuits that set hunger and satiety. As a board-certified neurologist, Dr. Kamen pays close attention to how these centrally acting medications affect appetite, energy, and mood, beyond the number on the scale.
How are approved weight-management options evaluated?
There is no universal first-line answer. The right medication depends on your BMI, prior weight-loss attempts, comorbidities, medical history, current medications, lab work, and goals. At our Las Vegas peptide clinic, that choice is made only after a complete $88 evaluation with Dr. Charles Kamen, MD - never by default dose or marketing.
We do not auto-prescribe the highest-dose version of any medication, and we do not promise specific weight-loss results. Protocols are designed individually and supervised over time. If GLP-1 therapy is not appropriate for you, you get that answer directly.
What to expect from a 2026 GLP-1 evaluation
The initial evaluation includes discussion of your medical history, current medications, and goals. Any required laboratory testing, ongoing management, and medications have separate costs. Ask for the written scope and cost before agreeing to care. A prescription or treatment plan is not guaranteed; any further decisions follow clinical assessment and relevant test results.
That protocol may include peptide therapy, NAD+, prescription weight-loss medications, hormone optimization, IV therapy, or targeted lifestyle changes - but only after evaluation and only when medically appropriate. The goal is durable metabolic improvement, not the fastest possible drop on the scale.
Protecting muscle while losing fat
Rapid weight loss reduces both fat and muscle, so a well-run GLP-1 protocol works to protect lean mass while it lowers fat. Supervised care pairs the medication with adequate protein, resistance training, and monitoring, so more of the weight lost is fat - including the visceral fat around the organs that most affects long-term metabolic health.
Research on retatrutide is separate from available clinical care. Its receptor mechanism does not establish that it preserves muscle, is appropriate for an individual, or may lawfully be prescribed as routine treatment.
In short
- Semaglutide is a single GLP-1 receptor agonist, FDA-approved for chronic weight management.
- Tirzepatide is a dual GLP-1/GIP agonist, FDA-approved for chronic weight management.
- Retatrutide is an investigational triple-receptor agonist, not FDA-approved, and cannot be legally compounded under federal law.
- There is no universal first-line GLP-1 - the right choice depends on BMI, comorbidities, medications, labs, and goals, not marketing.
- A supervised protocol protects muscle with protein and resistance training while targeting visceral and hepatic fat rather than scale weight alone.
- Approved medications require an individual prescribing decision. The $88 evaluation does not provide access to retatrutide; management and medication costs are charged separately, and laboratory testing is included in the management fee.
Common Questions
Which GLP-1 medication is right for me in 2026?
There is no universal first-line answer. The right choice depends on your BMI, prior attempts, comorbidities, current medications, labs, and goals - and on your response over time. A physician-led evaluation sorts this out. See our Las Vegas peptide clinic page to schedule.
How much do GLP-1 medications cost in Las Vegas?
The initial medical evaluation is $88 and includes a consultation, review of your history and goals, and lab orders when appropriate. Laboratory testing, ongoing physician management, and medications are separate charges. Ask for a written estimate before agreeing to care. See our peptide therapy cost in Las Vegas guide.
Do you serve Henderson patients for GLP-1 therapy?
Yes. Most of our weight-management patients come from Henderson, Green Valley, Anthem, and Seven Hills, and care is supervised the same way wherever you live in the valley. See our Henderson peptide clinic page for details and scheduling.
Will I lose muscle on a GLP-1 medication?
Any rapid weight loss can reduce muscle along with fat, so a supervised protocol works to prevent it. Adequate protein intake, resistance training, and monitoring help preserve lean mass, so more of the weight you lose is fat. This is a core reason GLP-1 therapy should be physician-supervised.
Do GLP-1 medications reduce visceral or belly fat?
They reduce overall body fat, including the visceral fat packed around the organs that most affects metabolic health. The glucagon component of retatrutide is of particular interest for mobilizing liver and abdominal fat. Because scale weight alone can mislead, body composition and labs are tracked to confirm the fat you are losing.
Is retatrutide available in Las Vegas in 2026?
Retatrutide is not an FDA-approved prescription option. FDA states that it cannot be compounded under federal law. An evaluation does not provide access to retatrutide; approved weight-management options are a separate clinical decision.
In 2026, Las Vegas patients have several approved GLP-1 options - and the right next step is a complete medical evaluation by a physician who designs and supervises protocols individually. Schedule at our Las Vegas peptide clinic or our Henderson peptide clinic.
References
- Jastreboff AM, et al. NEJM. 2022;387(3):205-216.
- Wilding JPH, et al. NEJM. 2021;384(11):989-1002.
- Jastreboff AM, et al. NEJM. 2023;389(6):514-525.
Have a question about your situation?
Bring your questions and recent history to board-certified neurologist Dr. Charles Kamen, MD. The evaluation is $88 and is applied toward your protocol if you continue care.